Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C32H43N5O5.CH4O3S |
Molecular Weight | 673.82 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N3C(=O)[C@](NC(=O)[C@H]4CN(C)[C@]5([H])CC6=CNC7=C6C(=CC=C7)[C@@]5([H])C4)(O[C@@]23O)C(C)C
InChI
InChIKey=TZGKQIBPZOZAKF-PJLVGBPESA-N
InChI=1S/C32H43N5O5.CH4O3S/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20;1-5(2,3)4/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38);1H3,(H,2,3,4)/t20-,22-,24-,25+,26+,31-,32+;/m1./s1
Dihydro-alpha-ergocryptine is an ergot alkaloid that has an agonist activity on D2 dopaminergic receptors and a partial agonist activity on D1 receptors. It also demonstrated antagonistic activity towards alpha-adrenergic receptors. The drug was approved by FDA in combination with other alkaloids (dihydroergocornine, dihydroergocristine and dihydro-beta-ergocryptine mesylate salts) under the name Hydergine for the treatment of dimentia and cerebrovascular insufficiency.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13513239
Curator's Comment: # Takeda
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2095203 |
3.1 nM [Kd] | ||
Target ID: P14416 Gene ID: 1813.0 Gene Symbol: DRD2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11072749 |
4.7 nM [Ki] | ||
Target ID: P21728 Gene ID: 1812.0 Gene Symbol: DRD1 Target Organism: Homo sapiens (Human) |
35.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | HYDERGINE Approved UseFor the treatment of senility and cerebrovascular insufficiency. Launch Date1977 |
|||
Primary | HYDERGINE Approved UseFor the treatment of senility and cerebrovascular insufficiency. Launch Date1977 |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg 2 times / day multiple, oral Highest studied dose Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, 47-70 years n = 24 Health Status: unhealthy Condition: Parkinson disease Age Group: 47-70 years Sex: M+F Population Size: 24 Sources: |
|
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Disc. AE: Nausea, Hypotension... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: Hypotension (2 patients) Tremor (1 patient) Cramps (1 patient) Itching (1 patient) Erythema (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cramps | 1 patient Disc. AE |
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Erythema | 1 patient Disc. AE |
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Itching | 1 patient Disc. AE |
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Nausea | 1 patient Disc. AE |
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Tremor | 1 patient Disc. AE |
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Hypotension | 2 patients Disc. AE |
60 mg 1 times / day multiple, oral Dose: 60 mg, 1 times / day Route: oral Route: multiple Dose: 60 mg, 1 times / day Sources: |
unhealthy, 64 ±1.5 years n = 32 Health Status: unhealthy Condition: idiopathic Parkinson’s disease Age Group: 64 ±1.5 years Sex: M+F Population Size: 32 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/11197065/ |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/11197065/ |
likely | |||
unlikely | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes |
Sample Use Guides
The recommended dosage (in form of hydergine tablets containing dihydroergocornine, dihydroergocristine, dihydro-alpha-ergocryptine and dihydro-beta-ergocryptine mesylate salts in an approximate weight ratio of 1:1:1) in the US is 1 mg three times daily. In Europe and Japan, up to 12 mg of hydergine daily have been used without serious adverse effects.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7905201
Primary cultures of rat cerebellar granule cells were exposed to toxic concentrations (100 uM) of glutamate in Mg2+-free buffer. Repeated addition of dihydro-alpha-ergocryptine (100 nM-1 uM, once a day from the second day in culture, last addition 3 hr before the glutamate pulse) protected cerebellar granule cells against the toxic action of glutamate.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Z4I7BU58DN
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
1426902
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
Z4I7BU58DN
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
DTXSID20931605
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
14271-05-7
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
SUB13589MIG
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
C75933
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
238-163-7
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
DBSALT002361
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
100000079200
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY | |||
|
159729
Created by
admin on Fri Dec 15 15:24:01 GMT 2023 , Edited by admin on Fri Dec 15 15:24:01 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD